Patient-reported outcomes are superior in patients with Type2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: Results from a randomized, open-label study

Diabetic Medicine

Volumn 28, Issue 6, 2011, Pages 715-723

  Schmidt, W E ^a   Christiansen, J S ^b   Hammer, M ^c   Zychma, M J ^c   Buse, J B ^d  

^a ST JOSEF HOSPITAL   (Germany)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c NOVO NORDISK A S   (Denmark)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Exenatide; Liraglutide; Patient reported outcomes; Type2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; SULFONYLUREA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; DIET RESTRICTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EVALUATION AND FOLLOW UP; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT DURATION; WAIST HIP RATIO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955950106     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03276.x     Document Type: Article

References (28)

1. Watkins K, Connell CM. Measurement of health-related QOL in diabetes mellitus. Pharmacoeconomics 2004; 22: 1109-1126.
2. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type2 diabetes mellitus: a randomized, controlled, double-blind trial. J Am Med Assoc 1998; 280: 1490-1496.
3. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type2 diabetes. Diabetes Care 2002; 25: 458-463.
4. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002; 25: 2238-2243.
5. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type1 and type2 diabetes. Curr Med Res Opin 2005; 21: 1477-1483.
6. UK Prospective Diabetes Study Group. Quality of life in type2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS37). Diabetes Care 1999; 22: 1125-1136.
7. Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009; 26: 722-728.
8. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type2 diabetes mellitus. Treat Endocrinol 2005; 4: 361-370.
9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008; 31: 1-11.
10. Arulmozhi DK, Portha B. GLP-1 based therapy for type2 diabetes. Eur J Pharm Sci 2006; 28: 96-108.
11. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type2 diabetes. Diabetes Care 2007; 30: 1608-1610.
12. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. Liraglutide versus glimepiride monotherapy for type2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
13. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
14. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
15. Bode B, Hale PM, Hammer M, Testa MA, Garber AJ. Patient-reported outcomes in subjects with type2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride. 44th Annual Meeting of the European Association for the Study of Diabetes, Rome, Italy, 7-11 September 2008: P894.
16. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH et al. Liraglutide once a day versus exenatide twice a day for type2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
17. Bradley C. Diabetes Treatment Satisfaction Questionnaire. In: Bradley C, ed. Handbook of Psychology and Diabetes. Chur, Switzerland: Harwood Academic Publishers 1994: 111-132.
18. Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999; 22: 530-532.
19. Green J, Feinglos M. Update on type2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. Int J Clin Pract Suppl 2007; 154: 3-11.
20. Sundaram M, Smith MJ, Revicki DA, Elswick B, Miller LA. Rasch analysis informed the development of a classification system for a diabetes-specific preference-based measure of health. J Clin Epidemiol 2009; 62: 845-856.
21. Secnik Boye K, Matza LS, Oglesby A, Malley K, Kim S, Hayes RP et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type2 diabetes. Health Qual Life Outcomes 2006; 4: 80.
22. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D et al. Exenatide once weekly versus twice daily for the treatment of type2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
23. Bradley C. Feedback on the FDA's February 2006 draft guidance on patient-reported outcome (PRO) measures from a developer of PRO measures. Health Qual Life Outcomes 2006; 4: 78.
24. Lewis KS, Bradley C, Knight G, Boulton AJ, Ward JD. A measure of treatment satisfaction designed specifically for people with insulin-dependent diabetes. Diabet Med 1988; 5: 235-242.
25. Witthaus E, Stewart J, Bradley C. Improved psychological outcomes after initiation of insulin treatment in patients with typeII diabetes. Diabetologia 2000; 43: A205.
26. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Br Med J 2002; 325: 746.
27. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type1 diabetes. Diabet Med 2001; 18: 619-625.
28. Petterson T, Lee P, Hollis S, Young B, Newton P, Dornan T. Well-being and treatment satisfaction in older people with diabetes. Diabetes Care 1998; 21: 930-935.